La Merie

Contact
lamerie.com
+34933429197

La Merie S.L.

C/Casp 33 B, 4º 2ª
08010 Barcelona
Spain
+34933429197
lamerie.com
Contact
Profile Products News
Contact

About La Merie

The consultancy business of La Merie Business Intelligence was established in 2002 by Ulrich Martin, MD. Based on his extensive experience in the biopharmaceutical industry both as a physician specializing in pharmacology and as a co-founder and CEO of a product development biotech company, La Merie provides expert consultancy services in R&D, Competitive Intelligence and in Licensing to the biopharmaceutical industry. The team of La Merie SL currently consists of six collaborators responsible for R&D, Science, Business Development, Publishing, eCommerce, Webmastering and IT.

Read more about La Merie
Facts about La Merie
  • Focus : Service
  • Industry : IT

Product portfolio of La Merie

Product portfolio

Show all

News about La Merie

La Merie

18-Mar-2010 | business & finance

Biologics Sales 2009: Antibodies are the growth drivers

Double digit growth rates in classes of antibodies and selected proteins

Read news
La Merie

17-Aug-2009 | business & finance

Changes ahead in the coagulation factor market by new entrants and technologies

The worldwide market of recombinant and plasma derived coagulation factors grew to more than US$ 7.5 bln in 2008 and will be fundamentally challenged by over 40 projects in the R&D pipeline

Read news
La Merie

10-Mar-2009 | business & finance

TNF antibodies beat them all in Biologics Sales 2008

The Business Intelligence firm La Merie S.L. reported that anti-TNF antibodies were the best selling class of biologics in 2008 with total sales of US$ 16. ...

Read news
La Merie

12-Nov-2008 | business & finance

Trends in the diabetes drug pipeline 2008

Increasing prevalence of diabetes and an attractive market foster intense efforts in improving existing approaches and exploring new treatment modalities

Read news
La Merie

30-Oct-2008 | business & finance

The future of human insulin: tailored and oral

Prevailing human insulin analogs to be followed by tailored insulin analogs and insulins with optimized drug delivery solutions

Read news
La Merie

12-Sep-2008 | business & finance

Takeda reigns supreme among Japanese pharma companies

Modest growth rates of 2007 sales by on average 3.2% YoY reflects challenges imposed by the health care system and an aging product portfolio

Read news
La Merie

14-Aug-2008 | business & finance

The third generation of TPO mimetics are again biologics

After failure of 1st generation thrombopoietic growth factors due to immunogencity, the 2nd generation is focused on oral TPO mimetics, now followed by a 3rd generation of engineered biologics with potential for higher potency and efficacy

Read news
La Merie

11-Aug-2008 | business & finance

The changing marketplace of antithrombotics: better than cheaper?

Next generation anticoagulant and antiplatelet agents have shown superiority over the current market leaders in clinical studies and are to challenge them before generics

Read news
Show more news about La Merie

Here you will find La Merie S.L.